STEMRAD INC.
TAMPA, FLORIDA

StemRad Inc., headquartered in Tampa, Florida, is a pioneering company specializing in the development of advanced personal radiation protection solutions. The company emerged from a collaborative vision by co-founders Dr. Oren Milstein and Daniel Levitt in November 2011. StemRad's flagship product, the 360 Gamma, represents a paradigm shift in protective technology for first responders such as firefighters and astronauts subjected to high levels of gamma radiation. This innovation focuses on safeguarding vital bone marrow located predominantly in the pelvic region while allowing complete mobility—a significant advancement over traditional, cumbersome full-body protection methods. The technological framework underlying the 360 Gamma relies on shielding partial body regions rich with stem cells, enabling biological recovery post-exposure through the body's inherent regenerative processes. This selective shielding is pivotal for reducing acute radiation syndrome (ARS) risks and other long-term health implications like cancer resulting from chronic low-dose exposures. Dr. Oren Milstein continues to spearhead research and development efforts as CEO since February 2016, supported by an accomplished leadership team featuring CTO Dr. Gideon Waterman, Business Development Director Mr. Busseau, and others leveraging international regulatory consulting expertise from Wanaka Capital Partners. StemRad's operations emphasize innovation and safety for critical workforce segments globally. The company has attracted significant attention and funding from top-tier investors in both life sciences and tech sectors across Israel and the United States, bolstered by strategic guidance from advisors like Dr. Leonard Gale—a renowned authority in radiation health effects with extensive relief coordination experience worldwide. StemRad stands as an equal opportunity employer committed to advancing the field of personal safety through cutting-edge scientific breakthroughs, as reflected in its robust corporate governance and ongoing research initiatives documented on stemrad.com.